Skip to content
DataLookout
Menu

VICTORION-2PNCT05030428

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 39 versions: 38 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Trial sites expanded: 983 → 989 locations
    • Publications: details revised at 1 of 1 entry
  2. Minor Trial sites reduced: 989 → 983 locations
    • Primary and study completion moved earlier from Oct 13, 2027 to May 10, 2027
    v38
  3. Minor Site details revised at 6 of 989 sitesv37
  4. Minor Study sites: 991 to 989v36
  5. Minor Study sites revised (991)v35
Show 32 earlier versionsHide 32 earlier versions
  1. Minor Site details revised at 72 of 991 sitesv34
  2. Minor Study sites revised (991)v33
  3. Minor Study sites revised (991)v32
  4. Minor Study sites: 986 to 991v31
  5. Minor Study sites: 989 to 986v30
  6. Minor Study sites: 994 to 989v29
  7. Minor Study sites: 993 to 994v28
  8. Minor Study sites: 985 to 993v27
  9. Minor Study sites: 986 to 985v26
  10. Minor Study sites: 992 to 986v25
  11. Minor Enrollment target: 17006 to 17004
    • Study sites: 995 to 992
    v24
  12. Minor Enrollment target: 17013 to 17006
    • Study sites: 1008 to 995
    v23
  13. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 16500 to confirmed 17013
    • Study sites: 1071 to 1008
    v22
  14. Minor Site details revised at 3 of 1071 sitesv21
  15. Minor Study sites: 1072 to 1071v20
  16. Minor Study sites: 1069 to 1072v19
  17. Minor Study sites: 1067 to 1069v18
  18. Minor Study sites: 1063 to 1067v17
  19. Minor Study sites: 1059 to 1063
    • Secondary endpoints: 3 to 4
    v16
  20. Minor Study sites: 1045 to 1059v15
  21. Minor Study sites: 1033 to 1045v14
  22. Minor Study sites: 1031 to 1033v13
  23. Minor Enrollment target: 15000 to 16500
    • Study sites: 820 to 1031
    v12
  24. Notable Primary and study completion dates pushed to Oct 13, 2027
    • Study sites: 790 to 820
    v10
  25. Notable Eligibility criteria shortened, about 1 word
    • Study sites: 473 to 790
    • Primary completion date: Oct 13, 2027 to Jan 4, 2027
    • Study completion date: Oct 13, 2027 to Mar 15, 2027
    v9
  26. Notable Primary and study completion dates pushed to Oct 13, 2027v8
  27. Minor Study sites: 406 to 473v7
  28. Minor Study sites: 373 to 406v6
  29. Minor Study sites: 310 to 373v5
  30. Minor Study sites: 123 to 310v4
  31. Minor Study sites: 2 to 123v3
  32. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Nov 30, 2021 to Nov 23, 2021
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events)
Timeframe: From randomization to total follow-up time (up to 72 months)

Secondary (4)

Time to Occurrence of Cardiovascular (CV) Death
Time to First Occurrence of 4P-MACE (4-Point Major Adverse Cardiovascular Events)
Time to first occurrence of Major Limb Adverse Events (MALE)
Time to occurrence of all-cause death

Arms and interventions

Inclisiran sodiumExperimental

Subcutaneous injection

PlaceboPlacebo comparator

Subcutaneous injection

Drugs: Inclisiran sodium 300 mg, Placebo

Sites

989 sites in 50 countries

United States 271, China 50, Spain 48, India 41, Canada 34, France 32, Brazil 30, Argentina 29, Bulgaria 26, Czechia 26, Poland 25, Netherlands 22, Slovakia 21, Hungary 20, Romania 19, South Africa 18, South Korea 17, Australia 16, Italy 16, Mexico 15, Belgium 13, Colombia 13, Serbia 13, Japan 12, Portugal 12, Chile 9, Croatia 9, Denmark 9, Lithuania 9, Sweden 9, Turkey (Türkiye) 9, Israel 8, Latvia 8, Norway 8, Estonia 7, New Zealand 7, Taiwan 7, Greece 6, Malaysia 6, Thailand 6, Finland 5, Puerto Rico 5, Philippines 4, Russia 4, Singapore 4, Slovenia 4, Austria 2, Iceland 2, Mauritius 2, Kenya 1